Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.
Williams DS, Mouradov D, Browne C, Palmieri M, Elliott MJ, Nightingale R, Fang CG, Li R, Mariadason JM, Faragher I, Jones IT, Churilov L, Tebbutt NC, Gibbs P, Sieber OM. Williams DS, et al. Among authors: mariadason jm. Mod Pathol. 2020 Mar;33(3):483-495. doi: 10.1038/s41379-019-0353-2. Epub 2019 Aug 30. Mod Pathol. 2020. PMID: 31471586 Free article.
Biomarkers of 5-FU response in colon cancer.
Mariadason JM, Tebbutt NC. Mariadason JM, et al. Cancer Biol Ther. 2011 Apr 15;11(8):771-2. doi: 10.4161/cbt.11.8.15109. Epub 2011 Apr 15. Cancer Biol Ther. 2011. PMID: 21343696 Free article. No abstract available.
Villin expression is frequently lost in poorly differentiated colon cancer.
Arango D, Al-Obaidi S, Williams DS, Dopeso H, Mazzolini R, Corner G, Byun DS, Carr AA, Murone C, Tögel L, Zeps N, Aaltonen LA, Iacopetta B, Mariadason JM. Arango D, et al. Among authors: mariadason jm. Am J Pathol. 2012 Apr;180(4):1509-21. doi: 10.1016/j.ajpath.2012.01.006. Epub 2012 Feb 18. Am J Pathol. 2012. PMID: 22349300 Free PMC article.
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC. Weickhardt AJ, et al. Among authors: mariadason jm. J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12. J Clin Oncol. 2012. PMID: 22412142 Clinical Trial.
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.
Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, Day F, Li S, Tsui C, Lipton L, Desai J, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Zhu HJ, Mariadason JM, Burgess AW, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM. Fleming NI, et al. Among authors: mariadason jm. Cancer Res. 2013 Jan 15;73(2):725-35. doi: 10.1158/0008-5472.CAN-12-2706. Epub 2012 Nov 8. Cancer Res. 2013. PMID: 23139211
150 results